Biopharmaceutical Services: Accelerating Discovery and De-Risking Approval for Market Access.

End-to-end non-clinical, CMC, clinical, and regulatory solutions engineered to guide complex biologics and advanced therapies through every lifecycle milestone.

Bringing a biopharmaceutical product to market is one of the most demanding undertakings in the life sciences industry.

The pathway from early discovery through regulatory approval and post-launch expansion requires precise, coordinated expertise across science, global regulation, quality, and clinical operations. These disciplines must move in sync across multiple geographies while continually adapting to evolving global regulatory frameworks.

PLG supports biopharmaceutical innovators at every stage of this journey. Powered by senior scientists, regulatory strategists, and clinical trial experts, we provide targeted solutions for large multinationals managing complex biologic portfolios as well as emerging biotechs bringing their first asset to market.

Whether navigating non-clinical safety studies, establishing robust CMC frameworks, managing global health authority submissions, or driving post-approval lifecycle strategies, PLG delivers the cross-functional depth and global reach needed to de-risk critical decisions and accelerate time-to-market. 

Strategic Capabilities Across the Biopharma Lifecycle

Our integrated biopharmaceutical practice provides technical expertise across every core development and operational pillar.

1_Specialized-consultants-or-scientists-in-regulatory-activities-1920x900-1
Biopharmaceutical Drug Development Services

Expert biopharmaceutical consultants accelerating your drug from discovery to launch with proven strategies

next-arrow
1_Regulatory-Affairs_Landing-Page
Regulatory Affairs Services

Comprehensive global regulatory support for all product types and lifecycle stages, backed by decades of local and international expertise.

arrow
1_Experts-research-professionals-scientist-in-a-group-working-on-a-drug-development-1920x900-1
CMC & Quality: Pharma's Pathway to Excellence

Guiding drug development to regulatory approval, ensuring safe, high-quality medicines.

arrow
1_Research-documents-in-a-table-1920x900-1
Non-Clinical and Toxicology Development

Design and oversee non-clinical programs bridging discovery to first-in-human trials, ensuring IND readiness, GLP oversight and CRO governance.

arrow
solution
Clinical Development Services

Integrated clinical development operations delivering strategy, adaptive trial design, robust CRO governance, GxP quality, global execution for regulatory success.

arrow

Frequently asked questions

PLG works with large multinationals managing complex biologic portfolios and with emerging biotechs bringing their first asset to market. Support is scaled to the company: from targeted expertise on a single question to an integrated programme covering non-clinical, CMC, clinical, regulatory and lifecycle activities.

Yes. PLG supports complex biologics and advanced therapies, whose manufacturing processes, comparability requirements and regulatory pathways differ significantly from small molecules. Senior scientists, CMC specialists and regulatory strategists work together to address these specific challenges from early development through to approval and beyond.

PLG designs and oversees the non-clinical programme needed to bridge discovery to first-in-human trials, including GLP oversight and governance of the CROs running the studies. It then assembles the regulatory package, so that safety data, CMC information and the clinical plan are consistent when submitted to the authority.

Chemistry, Manufacturing and Controls (CMC) demonstrates that a product can be manufactured consistently at the required quality. For biologics, small process changes can affect the product, so CMC strategy must anticipate scale-up and comparability. Weak CMC is a frequent cause of review delays, which is why PLG integrates it with regulatory and clinical planning.

Yes. PLG manages submissions to the EMA, the FDA and national authorities worldwide, coordinating content and timing across regions. With coverage of 150+ countries, PLG helps companies plan the sequence of filings and adapt dossiers to local requirements without losing consistency.

It includes clinical strategy, adaptive trial design, CRO governance, GxP quality oversight and global execution. The goal is evidence that is robust, submission-ready and aligned with what payers will later expect, so that the same data supports both approval and reimbursement.

Yes. PLG's lifecycle management keeps products compliant, competitive and accessible as markets evolve, requirements change and portfolios grow. This includes regulatory maintenance, pharmacovigilance, quality and market access, delivered by the same group that supported development.